Related Experiment Video
Updated: Jun 1, 2026

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
Published on: June 8, 2020
Evaluation of DNA polymerase beta gene mutation as a genetic marker for colorectal carcinoma
T Shimoyama1, K Ookawa, T Endo
1HIROSAKI UNIV,SCH MED,DEPT INTERNAL MED 1,HIROSAKI,AOMORI 036,JAPAN. HIROSAKI UNIV,SCH MED,DEPT BIOCHEM 2,HIROSAKI,AOMORI 036,JAPAN.
Abstract:
DNA polymerase beta is known to be involved in repair of DNA damage. Frequent mutation of its gene in the segment encoding amino acids 149-297 has been reported in colorectal cancer. To investigate whether mutation in this region is available as a genetic marker for colorectal cancer, 11 primary tumors and 4 liver metastases from 11 patients were examined by fragment length analysis and single-strand conformation polymorphism (SSCP) analysis of reverse-transcription polymerase chain reaction (RT-PCR) products. Although allelic imbalance in the p53 and DCC genes were observed in ten out of eleven primary tumors and all liver metastases using a dinucleotide repeat polymorphism, mutation was not detected in the DNA polymerase beta mRNA. Neither was it detected in seven colon cancer cell lines. Present results suggest that mutation in this region is uncommon in colorectal cancers and is not a useful genetic marker for colorectal cancer.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
PCR - Polymerase Chain Reaction
